Wells Fargo’s BriaCell Therapeutics BCTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4 Hold
1
– – ﹤0.01% 7214
2026
Q2
$3 Hold
1
– – ﹤0.01% 7185
2026
Q1
$4 Hold
1
– – ﹤0.01% 7037
2025
Q4
$7 Hold
1
– – ﹤0.01% 6923
2025
Q3
$11 Sell
1
-2
-67% -$21 ﹤0.01% 6820
2025
Q2
$94 Hold
3
– – ﹤0.01% 6485
2025
Q1
$116 Buy
3
+1
+50% +$48 ﹤0.01% 6360
2024
Q4
$164 Hold
2
– – ﹤0.01% 6381
2024
Q3
$360 Buy
+2
New +$225 ﹤0.01% 6190

Other funds holding BCTX

Wells Fargo's BCTX Position: Q3 2026 in Review

Wells Fargo held its BriaCell Therapeutics (BCTX) position steady in Q3 2026 at 1 share worth $4. The position accounts for ﹤0.01% of the portfolio, ranked #7214.

Wells Fargo first reported a position in BCTX in Q3 2024 and has held it in 9 quarters since. The position peaked at $360 in Q3 2024. 19 funds tracked by Wall St. Rank hold BCTX as of Q3 2026.

  • Wells Fargo held 1 share of BriaCell Therapeutics worth $4 as of Q3 2026.
  • Wells Fargo left its BriaCell Therapeutics share count unchanged in Q3 2026.
  • BriaCell Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q3 2026, its #7214 holding.
  • Wells Fargo first reported a position in BriaCell Therapeutics in Q3 2024 and has held it in 9 quarters since.
  • Wells Fargo's BriaCell Therapeutics position peaked at $360 in Q3 2024.
  • 19 funds tracked by Wall St. Rank held BriaCell Therapeutics as of Q3 2026.

Based on Wells Fargo's 13F filing for Q3 2026, filed 16 Nov 2026.